Olverembatinib is a protease inhibitor type drug, belonging to the class of small-molecule protein tyrosine kinase inhibitors. It can effectively block the activity of both the normal form (wild-type) and multiple mutant forms (including T315I, E255K, G250E, H396P, M351T, Q252H, and Y253F mutations) of Bcr-Abl tyrosine kinase. This drug is specifically indicated for the treatment of adult patients with chronic myeloid leukemia who harbor the T315I gene mutation, suitable for patients in the chronic phase or accelerated phase of the disease.
What conditions can Olverembatinib tablets be used to treat?
Patients who have developed resistance to other tyrosine kinase inhibitors (requiring confirmation of the T315I gene mutation through standard laboratory testing).
Adult patients diagnosed with chronic myeloid leukemia in the chronic phase or accelerated phase (in whom the growth rate of cancer cells is at a moderate level).
The mechanism of action of the drug is to precisely inhibit various forms of Bcr-Abl tyrosine kinase, blocking the abnormal proliferation signals of cancer cells (the T315I mutation refers to a specific genetic variation in leukemia cells that causes most targeted drugs to become ineffective).
What symptoms can Olverembatinib tablets help alleviate?
Patients confirmed to have the T315I gene mutation through standardized testing (requiring a diagnosis via a genetic testing report from a professional medical institution).
Cases showing poor response or drug resistance after treatment with other tyrosine kinase inhibitors (drug resistance manifests as the drug gradually losing efficacy, with suboptimal disease control).
Adult patients with chronic myeloid leukemia in the chronic phase or accelerated phase (the chronic phase refers to a relatively stable stage of the disease, while the accelerated phase indicates that the disease has begun to worsen but has not yet entered the most critical stage).
What drugs are Olverembatinib tablets commonly used with?
Patients must not self-administer other drugs in combination and must strictly follow a doctor's guidance. Because individual differences exist among patients regarding genetic mutation status, disease stage, and drug response, the doctor will evaluate whether combination therapy is necessary based on specific clinical characteristics (including blood test results, genetic testing reports, and prior medication history) and formulate a personalized treatment plan.
Pre-Administration Notices
Before use, confirm whether there is a history of drug allergy or severe liver disease. Pregnant women, breastfeeding women, and individuals with moderate hepatic or renal impairment should also use the drug with caution. During the course of treatment, concurrent use of other drugs that may cause interactions should be avoided, and physical condition should be monitored regularly. Specific precautions must be evaluated and determined by a professional doctor based on individual circumstances.
Who is strictly prohibited from using Olverembatinib tablets?
The following two groups of people will face severe health risks when using this drug and must absolute not use it:
Individuals who are allergic to the drug components;
Patients with severely impaired liver function (medically known as severe hepatic insufficiency).
Who needs to use Olverembatinib tablets with caution?
Patients with the following conditions need special attention and must have their risks and benefits evaluated by a doctor before deciding whether to use the drug. During the treatment process, physical reactions should be closely observed, and medical attention should be sought immediately if any discomfort occurs:
Women during pregnancy;
Women currently breastfeeding;
Patients with moderate hepatic impairment;
Patients with moderate or severe renal impairment;
Individuals who sunburn easily or need prolonged exposure to intense sunlight (animal studies suggest the drug may increase the risk of photosensitivity).
Can special populations use Olverembatinib tablets?
Pregnant women: Use with caution;
Breastfeeding women: Breastfeeding is prohibited during treatment and for at least 7 days after discontinuation;
Pediatric use: There are currently no relevant research data available;
Geriatric use: Targeted research data are temporarily lacking;
Patients with abnormal liver function: Use with caution in those with moderate impairment, and prohibited in those with severe impairment;
Patients with abnormal kidney function: Use with caution in those with moderate or severe impairment.
What are the drug interactions with Olverembatinib tablets?
Special attention should be paid to the changes that occur when combined with the following drugs:
Combined with itraconazole (a strong CYP3A4 inhibitor): Increases the maximum blood concentration of olverembatinib by 76% and total systemic exposure (AUC) by 159%;
Combined with rifampin (a strong CYP3A4 inducer): Decreases the maximum blood concentration of olverembatinib by 61% and total systemic exposure by 75%;
Combined with P-gp or BCRP transporter inhibitors: May affect the absorption process of the drug in the intestinal tract;
Combined with gastric acid suppressants: Because the drug dissolves more easily in an acidic environment, it is recommended not to concurrently use drugs that suppress stomach acid (such as proton pump inhibitors), as these drugs will affect the absorption efficacy of olverembatinib.
Frequently Asked Questions by Patients
If Olverembatinib has expired or its outer packaging is damaged, can medication still be continued?
Expired medications must not be taken, and use is prohibited when the physical characteristics of the drug have changed.
What are the matters that require attention when taking this product?
When taking the tablets, they must not be crushed or cut, and must be swallowed whole;
During the period of taking this product, try to avoid sun exposure or adopt appropriate sun protection measures. Patients who cannot avoid prolonged sun exposure or are sensitive to sunlight should use this product with caution.
